



# IPMPC

International Pharmaceutical &  
Medical Device Privacy Consortium

**2024** YEAR IN REVIEW

# Contents

Letter from IPMPC Chair & Vice Chair	1
Mission	2
Privileges of Membership	3
2024 By the Numbers	4
Insights from Our Members	5
European Working Group	7
US Working Group	8
Artificial Intelligence (AI) Working Group	9
Asia-Pacific & China Privacy Compliance Roundtables	10
Latin America & Canada Roundtable	11
2024 Ongoing Topic-Focused Initiatives	12
What to Expect from the IPMPC in 2025	13
2024 Member Companies	14
Board of Directors	15
IPMPC Secretariat	16

# Letter from the IPMPC Chair



**Alejandro Gené**  
*Chief Privacy Officer*  
Bristol Myers Squibb

Dear IPMPC Members and Community,

We are proud to share with you the 2024 IPMPC Year in Review! In reflecting on the past year, I am grateful to all IPMPC member companies and representatives for supporting the consortium and facilitating outstanding collaboration and thought leadership. We are in a remarkable time in history and IPMPC continues to meet us where we are – bringing together the global life sciences industry to advance members' compliance with privacy, security, AI, and other digital governance obligations, with the ultimate aim of supporting innovation in health diagnostics, treatments, and disease prevention, and enabling the delivery of life-saving and quality-enhancing health care to patients. IPMPC continues to maintain a robust portfolio of working groups, roundtables and timely initiatives and is committed to ensuring that the consortium remains proactive, practical and collaborative.

As you will read in more detail in the pages that follow, among its many initiatives, IPMPC sustained efforts to understand the changing US privacy and AI legislative landscape and its impact on life sciences companies. The IPMPC AI workstream expanded to provide more industry-specific resources for responsible AI governance. IPMPC organized a life sciences privacy symposium in Zurich, Switzerland, hosted by Baxter. The consortium also continued its regular engagement with MedTech Europe and EFPIA, culminating with a meeting in Brussels that included industry benchmarking and a fireside chat with a European data protection authority. The Asia-Pacific and Latin America and Canada Roundtables hosted a series of discussions with local experts on new laws and regulations in these regions and discussed the impact on the life sciences industry. The Middle East/Africa Privacy Roundtable was launched in late 2024 and will organize more regular gatherings in 2025.

As my two-year term as IPMPC Chair concludes, I congratulate and thank all IPMPC member companies for advancing innovative privacy and AI solutions to protect patients. It has been a distinct privilege to play a leadership role these past several years and I am sincerely grateful for your engagement and support. The generous collaboration of the IPMPC community is noteworthy. For those involved in the IPMPC, no explanation is needed—you experience this unique industry partnership on every call and at every meeting. For those not participating in the IPMPC but working in privacy and helping steer responsible AI governance in the life sciences industry, this report is an invitation to learn more about the consortium. We hope you will join us in 2025.

We look forward to another year of active engagement and optimal collaboration in the IPMPC!

# Letter from the IPMPC Vice Chair



**Charlie Blanchard**  
*Chief Privacy Officer*  
Amgen

2024 was another excellent year for IPMPC. I am grateful to have served as the Vice Chair of this vibrant consortium and am excited to begin my term as IPMPC Chair in 2025. The IPMPC continues to grow and advance key initiatives to support our global work as life sciences industry privacy, AI, legal, and compliance professionals. As we begin another year of collaboration, I want to thank Alejandro Gené, Chief Privacy Officer of BMS, for his generous Board leadership and support. Under his leadership, IPMPC has grown its membership, expanded its portfolio of projects and resources, and fostered collaborative engagement with industry stakeholders such as MedTech Europe, AdvaMed, BIO, EFPIA, ACRO, and RDPAC. I encourage all in the IPMPC community and beyond to stay in touch in 2025 by following the consortium on [LinkedIn](#) and keeping abreast of the consortium's progress via the consortium's [website](#). We look forward to a great year!

# Our Mission



Provide a forum to ensure that the global life sciences industry speaks with one, coherent voice on data privacy issues



Advance the protection of individual privacy



Augment member companies' data protection capabilities through the development and sharing of industry best practices



Anticipate and respond to new challenges affecting the protection of health information



Educate internal and external stakeholders on data protection in the industry and the importance of data innovation

# Privileges of Membership

**Access to extensive privacy-compliance resources** tailored to the needs of the pharmaceutical and medical device industry

**Timely analyses of new privacy laws, court decisions, and pharmaceutical and medical device enforcement actions** impacting business operations

**Updates on global privacy developments** and informative, practical discussions with local counsel from around the world

Opportunities to **interact with key regulators**

Cost-sharing to **efficiently leverage budget resources**

**Expert insight** into how evolving business models could be impacted by privacy laws

**Legal, project management, and logistical support** by the IPMPC Secretariat

Regular **interaction and benchmarking with industry colleagues** facing similar challenges

# 2024 By the Numbers

44



member companies

100+




teleconferences & virtual meetings

700+



individual members consisting of privacy & AI legal and compliance professionals representing IPMPC member companies

25



different topics addressed by aggregated benchmarking surveys, including the comprehensive bi-annual IPMPC survey of privacy programs & practices in the pharmaceutical & medical device industries

2



new initiatives launched: IPMPC Middle East & Africa Roundtable & IPMPC Privacy & AI Legislative Affiliate

20+



templates, summaries, & additional resources developed

4



submitted responses on proposed standards, legislation, & rulemakings



2 in-person IPMPC Global Life Sciences Privacy Summits: Washington, D.C. and Zurich

2 in-person IPMPC Board of Directors meetings

2 IPMPC networking receptions held for members and friends in conjunction with IAPP conferences

2 in-person workshops held: IPMPC Privacy Bootcamp and IPMPC tabletop exercise simulating a security incident within a medical device company

# Member Insights

"For the past seven years, Cook Medical has partnered with IPMPC, navigating challenges such as the COVID pandemic and evolving data privacy regulations together. IPMPC is led by dedicated professionals who, like its members, have made data privacy their life's work. The IPMPC team's expertise, collaborative spirit, and commitment to solving complex issues have been invaluable to our organization."



**Megan Charlesworth**  
*Chief Privacy Officer*  
Cook Medical

"The IPMPC is a trusted source for guidance and insight into key issues facing the industry, the latest regulatory and legal changes and most importantly, practical solutions that allow businesses to adjust as needed to the latest developments. I consider this membership to be one of the smartest investments I make each year."



**Lara Liss**  
*Chief Privacy and Data Trust Officer*  
GE HealthCare

"UCB joined the IPMPC recently and we couldn't be happier. What we found is a very diverse group of professionals, sharing the same challenges and interests, and always willing to support each other in very creative manners. Besides, the IPMPC Secretariat's team and the work they do represents a real game changer for us in terms of resources and brainstorming opportunities. This really helps move the needle in the right direction."



**Donovan Shepperd**  
*Head of Legal Data  
Privacy & DPO*  
UCB

"I find participating in the IPMPC calls and events is really valuable, because they not only help me to stay on top of the legislative developments, but more importantly, they trigger discussion with peers facing the same challenges. This facilitates understanding of how to operationalise the privacy requirements in the medical devices sector."



**Alessandra Colombo**  
*Senior Privacy Counsel*  
Cochlear

"I really enjoy being a member of the IPMPC. This is a fantastic consortium that gives us access to tremendous and extremely valuable resources. The level of information provided as well as all the practical resources made available are instrumental for us to stay abreast of all the developments in a constantly evolving landscape and address specific challenges we face in the industry. It also truly reflects how much the privacy community in the industry is willing to share knowledge and experiences and how helpful it is to engage with and get insights from other privacy colleagues. I would highly recommend the IPMPC to any company in the life sciences industry."



**Jessica Vialle**

*Global Privacy Officer & Data Protection Officer*  
**Jazz Pharmaceuticals**

"As an active member of the IPMPC European Working Group and a member of the IPMPC Board of Directors, I strongly believe that the IPMPC plays an important role in fostering collaboration between member companies, sharing best practices, and advocating for responsible data practices that interplay between Global and Region Europe. I envision the consortium becoming an even more influential entity, shaping global privacy standards and regulations, and driving innovation in privacy technology and practices within our industry, while we carefully monitor how the political changes might impact the existing Data Privacy Framework in the months to come."



**Eirini Tsotra**

*Global Privacy Officer*  
**Incyte**

"Year after year, the IPMPC is a primary resource for AbbVie's privacy office for data privacy developments, interpretation and implementation considerations, benchmarking, regional insights, and peer networking, all of which are specific, relevant, and timely to our industry. More recently, IPMPC has provided thought leadership, practical tools and a forum for the intersection of AI and data privacy. While AbbVie is part of numerous data privacy trade and policy groups, the IPMPC remains our most important partner to maintain and mature our global privacy program."



**Eric Berman**

*Vice President, Ethics & Compliance Officer, Chief Privacy Officer*  
**AbbVie**

"The IPMPC is an incredibly invaluable resource for Privacy professionals in our industry. It provides a unique platform for benchmarking with peers, allowing us to share best practices and learn from each other's experiences in real-time. In addition, the ability to receive updates on laws and regulations as they are developing is crucial in helping us stay ahead of regulatory changes and maintain compliance. Once the laws are passed, the access to template materials is extremely beneficial, as it helps streamline our processes and ensures we are aligned with industry standards. Being a part of the IPMPC has truly enriched our professional journey."



**Sara Berkson**

*Vice President, Chief Privacy Officer*  
**Vertex**



# IPMPC European Working Group



**Felix Czwikla**  
*European Working Group Co-Chair*  
**GlaxoSmithKline**



**Angélica Medrán**  
*European Working Group Co-Chair*  
**Jonhson & Johnson**

## 2024 Accomplishments:

- Monitored and provided summaries and updates on privacy developments in Europe, including in relation to the EU AI Act, the EU Data Act, the European Health Data Space, the NIS2 Directive, European Court of Justice key rulings, and guidance and enforcement actions by European data protection authorities.
- Provided opportunities for live benchmarking on priority topics, including preparation and compliance with forthcoming laws and regulations, AI governance, the changing scope of privacy teams, privacy program implementation, and managing data localization requirements.
- Hosted special sessions with guest speakers including a presentation on the evolving environment for generation of real-world evidence with a representative of EFPIA, and a discussion on privacy legislation in the healthcare sector with a member of the Spanish Data Protection Agency.
- Organized collaborative discussions with EFPIA and MedTech Europe members in Brussels to debrief on the IAPP Data Protection Congress, benchmark on European privacy hot topics, and engage in Q&A with a member of the Irish Data Protection Commission.
- Submitted comments on the French data protection authority's public consultation on reference standards for the processing of personal data in the context of health research.



**Sue Foster**  
*Technology Data Privacy Director, Global Clinical Solutions*  
**AstraZeneca**

"The IPMPC European Working Group has been a valuable resource for AstraZeneca during a period of fast-paced regulatory change. The meeting presentations and materials are high-quality. The discussions are well-informed and practical. Participating in the IPMPC is a very effective way to stay abreast of regulatory changes and get ahead of upcoming challenges. This past year, I was particularly impressed by the European Working Group's coordination of a rapid – but very thoughtful – collective response to an important consultation on a critical data protection framework for clinical trials in France."

# IPMPC US Working Group



## 2024 Accomplishments:



**Joanna Levin**  
*US Working  
Group Co-Chair*  
**Pfizer**



**Erin Geygan**  
*US Working  
Group Co-Chair*  
**Johnson & Johnson**


- Monitored privacy developments in the US at the state and federal level and provided summaries of key changes, including in relation to state privacy laws and regulations, guidance issued by state regulators, enforcement actions by state regulators and the Federal Trade Commission (FTC), and CIPA litigation.
- Provided opportunities for live benchmarking on priority topics, including on approaches to implementing compliance with the consumer health data laws, data and AI governance, and managing a global privacy program.
- Organized webinars on the US Privacy Landscape for Government Affairs Colleagues, US Privacy Overview for Marketing Colleagues, and a Summer Privacy Bootcamp.
- Created and regularly updated the 2024 IPMPC State Privacy Legislation Tracker.
- Updated and expanded IPMPC State Privacy Compliance Toolkit resources for compliance with new privacy laws.
- Submitted comments on the Department of Justice's Advanced Notice of Proposed Rulemaking and Notice of Proposed Rulemaking regarding Provisions Regarding Access to Americans' Bulk Sensitive Personal Data and Government-Related Data by Countries of Concern.



**Mita Lakhia**  
*Senior Associate General  
Counsel - Legal Privacy  
and Data Security,*  
**AbbVie**

"The IPMPC US Working Group has been an invaluable resource to help keep up and navigate the rapidly evolving US privacy landscape. These meetings are among the most valuable ones of my week! The up-to-date information provided by the Secretariat, combined with the active discussion with our industry peers, is incredibly helpful. At a global company, I often feel like our attention is drawn in so many different directions, but it is so appreciated to have this regular connection to focus on the US privacy space – which shows no sign of slowing down!"

# IPMPC Artificial Intelligence (AI) Working Group



**Katherine Lewis**  
*AI Working  
Group Co-Chair*  
**Regeneron**



**Lydia Knab**  
*AI Working  
Group Co-Chair*  
**Sanofi**

## 2024 Accomplishments:

- Reviewed requirements under the EU AI Act and the Colorado AI Act, and developed detailed chart breaking down and comparing these requirements by topic.
- Discussed members' approaches to inventorying AI uses, and created a template AI use case intake form and set of follow-up interview questions for uses that potentially trigger obligations under the EU AI Act and/or Colorado AI Act.
- Discussed principles for responsible development and deployment of AI, and how members have incorporated these principles into their AI governance programs.
- Provided opportunities for live benchmarking on members' approaches to structuring an AI governance program, managing risks associated with vendors' use of AI and licensing of AI tools, and internal training and guidance on AI requirements and best practices.
- Discussed how privacy and data protection requirements apply to training of AI systems using personal data, as well as risks and good practices with respect to the input of personal data into AI tools.



**Katherine Lewis**  
*Corporate Counsel, AI &  
Emerging Technology,  
Data Privacy & Security*  
**Sanofi**

"Being new to the biotech-pharma industry, I have been so impressed with the IPMPC. The team of dedicated professionals supporting this organization continually delivers high quality resources and programming in data privacy and artificial intelligence law that enable me and my team to stay abreast of continually changing legal developments and understand industry approaches to common challenges, practical insights and best practices, both as these emerge and evolve. As a resource, they have been invaluable. Just in 2024 alone, the resources the AI Working Group prepared have informed our team on a number of issues and enabled us to stay up to date on the quickly changing AI landscape. I am looking forward to continuing to work with the AI Working Group in 2025 to develop further resources and tools for AI and privacy professionals in the IPMPC, including providing a closer look at the potential interoperability between data privacy and AI risk assessments and staying abreast of practical solutions to some of the privacy challenges we face in the adoption and use of AI."

# Asia-Pacific & China Privacy Compliance Roundtables



**Viola Pan**  
*Asia-Pacific  
Roundtable Chair*  
**Organon**

## 2024 Accomplishments:

- Organized Roundtable meetings to discuss privacy and AI legislative and regulatory developments in the Asia-Pacific region and facilitate benchmarking on priority topics of interest.
- Organized China Privacy Compliance Roundtable meetings to provide overviews of and opportunities to benchmark on priority topics such as China's Cross-Border Data Transfer regulations.
- Webinar on data privacy in Vietnam – Presentation and Q&A with Tilleke & Gibbins.
- Webinar on privacy developments in South Korea – Presentation and Q&A with Bae, Kim & Lee.
- Facilitated ongoing panel discussions around India's Digital Personal Data Protection Act, featuring AZB & Partners, Shardul Amarchand Mangaldas & Co., and Vaish Associates.
- Submitted comments on Vietnam's draft personal data protection law.



**Lei Fang**  
*Asia-Pacific  
Roundtable Vice Chair*  
**Pfizer**



**Lei Fang**  
*Data Privacy  
Officer*  
**Pfizer**

"IPMPC Asia Pacific Roundtable provides an excellent opportunity to first keep us up to speed on the legislative development in the region by inviting country lawyers to introduce new/emerging laws, and second it is a great platform for benchmarking, sharing and learning from each other."



**Viola Pan**  
*China Compliance  
Officer, Business  
Practice Officer,  
Privacy Officer*  
**Organon**

"The biggest value of IPMPC membership is the access to a global network of collaborative privacy professionals and thought leaders. This network provides opportunities for timely knowledge of global privacy laws & regulations and sharing of valuable industry benchmarking and insights. The IPMPC is a unique forum that highlights best practices and practical solutions."

# Latin America & Canada Roundtable



**Andrea Walker-Modu**  
*Latin America & Canada  
Roundtable Co-Chair*  
**Bristol Myers Squibb**

## 2024 Accomplishments:

- Organized Roundtable meetings to discuss privacy and AI legislative and regulatory developments in Latin America and Canada and facilitated benchmarking on priority topics of interest.
- Established Roundtable alert system for members to stay apprised of key privacy and AI events impacting life science companies.
- Facilitated member presentations on AI Regulatory Developments in Brazil, Canada, and other Latin American jurisdictions.
- Webinar on privacy developments in Canada – Presentation and Q&A with Borden Ladner Gervais
- Webinar on privacy developments in Colombia – Presentation and Q&A with Philippi Prietocarrizosa Ferrero DU & Uria
- Webinar on data privacy in Chile – Presentation and Q&A with Bofill Mir Abogados
- Webinar on privacy developments in Mexico – Presentation and Q&A with Santamarina & Steta
- Facilitated panel discussion on Brazil privacy considerations, including the new clinical trial law, patient support programs, and the new DPO regulation, featuring Machado, Meyer, Sendacz and Opice Advogados.



**Guilherme Peretti**  
*Latin America & Canada  
Roundtable Co-Chair*  
**Organon**



**Guilherme Peretti**  
*Associate Director,  
Privacy & Data Protection*  
**Organon**

"2024 was a significant year for privacy in Latin America and Canada. We saw new privacy laws and regulations being approved or coming into effect, each within varying frameworks and jurisdictions. AI-related regulations and decisions also gained importance in the region. The Roundtable webinars and benchmark discussions were helpful for keeping up with these developments and understanding their impact on our industry. I truly appreciate the group's engagement in 2024 and look forward to the work ahead in 2025."



# 2024 Ongoing Topic-Focused Initiatives



## IPMPC & MedTech Europe Collaborative Medical Device Roundtable

- Organized joint discussions with MedTech Europe Data Protection Committee to focus on privacy issues for medical device and medical technology companies and identify benchmarking questions and discussion topics.
- Conducted joint benchmarking surveys with members of IPMPC and MedTech Europe on AI governance and risk management and international data transfers.



## IPMPC Privacy Stewardship & Privacy Champion Programs Project Team

- Maintained IPMPC Crowdsourcing Resource for Data Privacy Day.
- Facilitated benchmarking and ad-hoc discussions around key considerations for operating Privacy Stewardship and Privacy Champion Programs at life science companies.



# What to Expect from the IPMPC in 2025

## Middle East & Africa Roundtable

In response to the increasingly global nature of privacy and AI regulation and compliance requirements, the IPMPC organized a kickoff meeting to discuss key developments and priorities in the Middle East and Africa regions in the fall of 2024. The new Roundtable will meet quarterly in 2025 to monitor the privacy landscape in the Middle East and Africa, bring together members and guests on-the-ground, and identify opportunities for education, benchmarking, and the development of resources.

During Q3-Q4 2024, the Roundtable hosted the following sessions:

- Webinar on Data Privacy in Saudi Arabia – Presentation and Q&A with Al Tamimi & Co. and Al-Sharif Law
- Webinar on Data Privacy in Turkey – Presentation and Q&A with Hergüner Bilgen Üçer

## Increased Opportunities for Live Benchmarking Discussions

In addition to monthly IPMPC benchmarking surveys, ad-hoc benchmarking discussions during working group and roundtable meetings, and occasional in-person benchmarking sessions at IPMPC events, in 2025 the IPMPC will be implementing further opportunities for members to share insights, challenges, and best practices around top-of-mind privacy developments impacting the pharmaceutical and medical device industries.

Going forward, the IPMPC will:

- Organize bi-monthly virtual benchmarking meetings for live discussion of the monthly IPMPC benchmarking reports, which present the blinded and compiled results of member-submitted survey questions.
- Explore the feasibility of in-person, dedicated benchmarking meetings bringing together IPMPC members in their respective regions.

## IPMPC Privacy and AI Legislative Affiliate

As the life sciences industry continues to be impacted by new US comprehensive privacy and AI legislation and regulation at state and federal levels, several IPMPC members identified a need for increased support and cooperation with government affairs and policy colleagues at their companies as new legislation is introduced. In December 2024, the IPMPC stood up the Privacy and AI Legislative Affiliate (PAILA) in an effort to:

- Bring together privacy and AI subject matter experts and government affairs professionals
- Educate participants on legislative activity, trends, and developments
- Create ready-to-use resources to support members' advocacy efforts and facilitate industry alignment on key privacy and AI principles

In 2025, with the support of participating IPMPC member companies, the IPMPC PAILA will be intensely monitoring developments, creating educational and template material, and facilitating strategic alignment from January-April, while most legislatures are in session. From May-December, IPMPC PAILA will provide reduced support while continuing to review pending legislation, determine priorities, and educate members on key developments.

# Member Companies

Abbott Laboratories

AbbVie

Amgen

Amicus Therapeutics

Astellas Pharma

AstraZeneca

Baxter

Becton, Dickinson and Company

BeiGene

BioMarin

Boehringer-Ingelheim

Bristol Myers Squibb

Cochlear Limited

Cook Medical

Edwards Life Sciences

Eli Lilly and Company

Formation Bio

Fresenius Medical Care

GE HealthCare

Genentech/Roche

Gilead Sciences

GSK

Idorsia

Incyte

Insmed

Jazz Pharmaceuticals

Johnson & Johnson

Karl Storz

Kyowa Kirin

Madrigal Pharmaceuticals

Merck Sharp & Dohme

Moderna

Novartis

Novo Nordisk

Organon and Company

Otsuka Pharmaceutical Company

Pfizer

Regeneron Pharmaceuticals

Sanofi

Solventum

Stryker

Takeda Pharmaceutical Company

UCB

Vertex Pharmaceuticals



# Board of Directors



**Alejandro Gené**

*Chair of IPMPC*

Bristol Myers Squibb



**Charlie Blanchard**

*Vice Chair of IPMPC*

Amgen

## Planning Committee

Antonios Roussos *Astellas*

João Barreiro *BeiGene*

Laura Donahue *Eli Lilly*

Ivelisse Clausell *Johnson & Johnson*

Ashley Bashore *Novartis*

Amie Philips Pablo *Novo Nordisk*

Agatha O'Malley *Otsuka*

### Abbott Laboratories

Jacob Springer  
Ravi Kiran

### AbbVie

Eric Berman

### Amgen

Charlie Blanchard

### Astellas Pharma

Theresa Niland  
Antonios Roussos

### AstraZeneca

Amy Papili  
Laura Marchant

### Baxter

Efstathia Gkika  
Mary Deligianni

### Becton, Dickinson and Company

Luca Nevano

### BeiGene

João Barreiro

### Boehringer-Ingelheim

Linda Mancini

### Bristol Myers Squibb

Alejandro Gené  
Andrea Walker-Modu

### Cook Medical

Megan Charlesworth

### Edwards Life Sciences

Jeff Dennis  
Sadaf Djavadi

### Eli Lilly and Company

Laura Donahue  
Nick Merker

### Fresenius Medical Care

Dorene Stupski

### GE HealthCare

Lara Liss

### Genentech/Roche

Kimberly Gold  
Florian Zabel

### Gilead Sciences

Danielle Manner  
Silvia Sanna

### GSK

Catherine Baena  
Jesús Herranz

### Incyte

Amy Anderson  
Nick Apruzzi

### Jazz Pharmaceuticals

Rachel Ralston  
Jessica Vialle

### Johnson & Johnson

Ivelisse Clausell  
Erin Geygan

### Karl Storz

Erica Yen  
Reginald McKee

### Kyowa Kirin

Chad McManamy

### Merck Sharp & Dohme

Chris Foreman  
Melissa Fukushima

### Moderna

Zoe Philippides  
Marcus Sinha

### Novartis

Ashley Bashore  
Franziska Janorschke

### Novo Nordisk

Amie Philips Pablo

### Organon and Company

Terry-Ann Cooper  
Kelly Tyler

### Otsuka Pharmaceutical Company

David McKinney  
Agatha O'Malley

### Pfizer

Joanna Levin  
Chiara Formenti-Ujlaki

### Regeneron Pharmaceuticals

Patrice Ettinger

### Sanofi

Xavier Jean

### Solventum

Mohammad Amer

### Stryker

Gloria Greco  
Melissa Van Buhler

### Takeda Pharmaceutical Company

Rachel Chapman  
Vicky Perez-Riu

### UCB

Donovan Sheppard  
KB Borrelli

### Vertex Pharmaceuticals

Sara Berkson  
Michael Bullard

# IPMPC Secretariat

## In Support of the IPMPC, the Secretariat:

Prepares legal analyses and drafts  
compliance and training tools and materials

Coordinates regular industry benchmarking

Facilitates dialogue, consensus-building, and governance

Manages outreach and legislative contacts

Organizes teleconferences, meetings, and workshops

Prepares meeting agendas, summaries, and presentations

Serves as antitrust counsel

For more information and to stay  
up to date on IPMPC activities,  
visit [ipmpc.org](http://ipmpc.org) and follow the  
IPMPC's [LinkedIn Page](#). 

The law firm of Faegre Drinker Biddle & Reath LLP serves as Legal Counsel and Secretariat to the IPMPC. Composed of attorneys, scientists, and project managers, the Consortia Management Team forms and supports life sciences industry collaborations that help companies throughout the world address complex topics of mutual interest. For more than 25 years, the team's work with these collaborations has focused on issues impacting the pharmaceutical and medical device industries.

## IPMPC Membership Inquiries

Membership in the IPMPC is open to research-based medical device and pharmaceutical companies. Because membership is at the company level, members enjoy unlimited participation on IPMPC working groups and IPMPC educational webinars.

For questions about the IPMPC's priorities, progress, or membership, please email [info@ipmpc.org](mailto:info@ipmpc.org) or contact:



**Mary Devlin Capizzi**

[mary.devlincapizzi@faegredrinker.com](mailto:mary.devlincapizzi@faegredrinker.com)  
+1 202 230 5101



**Maureen Donahue Hardwick**

[maureen.hardwick@faegredrinker.com](mailto:maureen.hardwick@faegredrinker.com)  
+1 202 230 5133



**Peter A. Blenkinsop**

[peter.blenkinsop@faegredrinker.com](mailto:peter.blenkinsop@faegredrinker.com)  
+1 202 230 5142



**Reed Abrahamson**

[reed.abrahamson@faegredrinker.com](mailto:reed.abrahamson@faegredrinker.com)  
+1 202 230 5672



**Bridget Macaulay**

[bridget.macaulay@faegredrinker.com](mailto:bridget.macaulay@faegredrinker.com)  
+1 202 230 5111



IPMPC

International Pharmaceutical &  
Medical Device Privacy Consortium